

ADG106

Name: ADG-106

Synonyms: ADG 106

Indication: Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma Oncology

Company: Adagene

ADG106, a fully human agonistic monoclonal antibody (mAb) targeting a novel epitope of CD137 is currently in clinical trials conducted both in China and in the US, investigating its safety in advanced and/or refractory solid tumors and lymphomas. ADG106 Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma A Study of CD137 Agonist ADG106 Administered Intravenously in Patients with Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma (Protocol number: ADG106-1001) ADG-106 is a modified antibody that activates the CD137 receptor, which is found in key subsets of immune cells (T-cells and natural killer cells). By binding and activating the receptor, ADG-106 sends a stimulatory signal that increases the proliferation and activity of these immune cells, improving cancer fighting.

While other antibodies against CD137 already have reached clinical trials, their safety profile was somewhat discouraging, with some patients experiencing liver toxicity. But ADG-106 targets CD137 in a distinct manner, which supports its excellent safety profile, even at very high doses. The new compound also is better at fighting cancer than other CD137 antibodies. Consistent with its efficacy, studies in the laboratory have shown that ADG-106 strongly activates CD137, promoting T-cell proliferation and the production of key inflammatory molecules, or cytokines.